Skip to main content
Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.815
+0.195 (7.44%)
Mar 9, 2026, 1:26 PM EDT - Market open

Protalix BioTherapeutics Revenue

Protalix BioTherapeutics had revenue of $17.85M in the quarter ending September 30, 2025, a decrease of -0.60%. This brings the company's revenue in the last twelve months to $61.84M, up 35.42% year-over-year. In the year 2024, Protalix BioTherapeutics had annual revenue of $53.40M, down -18.47%.

Revenue (ttm)
$61.84M
Revenue Growth
+35.42%
P/S Ratio
3.66
Revenue / Employee
$290,329
Employees
213
Market Cap
226.39M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202453.40M-12.10M-18.47%
Dec 31, 202365.49M17.86M37.48%
Dec 31, 202247.64M9.29M24.22%
Dec 31, 202138.35M-24.55M-39.03%
Dec 31, 202062.90M8.21M15.00%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Keros Therapeutics 244.06M
Editas Medicine 40.52M
Voyager Therapeutics 31.32M
Alector 21.05M
Cibus 3.79M
Humacyte 1.57M
Revenue Rankings

PLX News

More News